Atara Biotherapeutics has entered into a strategic collaboration with Moffitt Cancer Center to develop multi‑targeted chimeric antigen receptor T-cell (CAR T) immunotherapies for patients with AML and B‑cell malignancies.    As part of the collaboration, Atara will gain access to novel CAR T targeting and co‑stimulation domains designed to improve T cell proliferation and enhance persistence. This agreement, along with Atara’s prior CAR T collaboration with Memorial Sloan Kettering Cance...